MemberHahahhahhhahhahahhaha Unlucky for you, drunk people are gonna pee on you. Feel for you.
Autifony Therapeutics Phase II Study for AUT00063, for the Treatment of Hearing Loss and Tinnitus
- Thread starter attheedgeofscience
- Start date
Hahahhahhhahhahahhaha Unlucky for you, drunk people are gonna pee on you. Feel for you.
Christian78
Member
- Dec 17, 2013
- 965
- Tinnitus Since
- (Sep 2013)
- Cause of Tinnitus
- progressive tinnitus, time of expiring in next 3-6 months
coming out in EU or? How we will test it? (will it be me buying it illegally in south west or east Europe, Switzerland or obtaining it legally in Sweden?
It just completed phase IIII trials , and only for epilepsy.
https://www.clinicaltrials.gov/show/NCT00464269
Christian, we will obtain it legally in España.
Next year in the US and EU
No, TT will probably again be doing another mini trial next year lol
Autifony Therapeutics recruits first trial patient
Released : 27 04 2015
RNS Number : 3319L
Imperial Innovations Group plc
27 April 2015
27 April 2015
Imperial Innovations Group plc
Autifony Therapeutics recruits first patient into Phase IIa trial for age related hearing loss
Imperial Innovations Group plc (AIM: IVO, "Innovations", "the Group") is pleased to note that portfolio company Autifony Therapeutics ("Autifony" or "the Company") has today announced that it has recruited the first subject in a Phase IIa study for treatment of age-related hearing loss.
This study (called CLARITY-1) will explore the potential of Autifony's lead product AUT00063, to improve hearing in the elderly by focusing on the discrimination of speech from background noise. The study will be conducted in around 14 key sites across the USA.
Age-related hearing loss is an area of significant unmet medical need affecting up to half of people over the age of 65. For some the onset can occur well before that time; with the UK charity Action on Hearing Loss estimating that 40% of over 50 year olds have some form of hearing loss.
The key complaint for those suffering from age-related hearing loss is difficulty understanding speech, in particular in noisy environments, or where several people are talking at the same time, such as at social gatherings. There are no current treatment options and whilst hearing aids or cochlear implants can help some sufferers, interpreting speech remains a challenge.
AUT00063 is a novel, first-in-class Kv3 potassium channel modulator and is also in development for the treatment of tinnitus, with a Phase IIa clinical trial in this indication already underway in the UK.
Maina Bhaman, Director of Healthcare Ventures, Imperial Innovations, said:
"Autifony's concept of using a pharmaceutical treatment to improve hearing is completely novel and CLARITY is a pioneering trial. It is also a significant milestone for Autifony in that it highlights the acceptance of the Company's first IND (Investigational New Drug) by the FDA.
"In addition to making good progress with its clinical trials into hearing disorders, Autifony has also recently announced a £3.3 million collaborative project to progress its new drug, AUT00206, which is being developed against the same Kv3 ion channel target, into clinical trials for the treatment of schizophrenia.
"This will be the company's second product in clinical trials and will be largely funded by an award of £2.4 million from the Biomedical Catalyst, jointly funded by Innovate UK and the Medical Research Council.
This funding will allow Autifony to initiate clinical trials to test the safety and tolerability of AUT00206, and also to continue its collaboration with the University of Manchester and Newcastle University on further in-depth research into the new drug's mechanism of action."
At 31 January 2015 the Group had a 25.1% interest in Autifony Therapeutics with a fair value of £6.1 million.
For further information contact:
Imperial Innovations Group plc
020 3053 8834
Russ Cummings, Chief Executive Officer
Jon Davies, Director of Communications
Instinctif Partners
020 7457 2020
Adrian Duffield/Melanie Toyne-Sewell
J.P. Morgan Cazenove (Nominated Adviser)
020 7742 4000
Michael Wentworth Stanley/Alec Pratt
Cenkos Securities
020 7397 8900
Christopher Golden
Notes to editors
About Imperial Innovations - www.imperialinnovations.co.uk
Imperial Innovations Group plc creates, builds and invests in pioneering technologies developed from the academic research within the 'Golden Triangle' broadly bounded by London, Cambridge and Oxford, which is home to the UK's four leading research-intensive universities.
This area is home to many new technology companies through its proximity to the academic communities of Imperial College London, the University of Cambridge, the University of Oxford and University College London, as well as other leading research institutions.
Imperial College London, the University of Cambridge, the University of Oxford and University College London collectively have research income of £1.4 billion per annum and are ranked as four of the top ten Universities in the world (source: QS World University Rankings 2014/15).
Innovations supports scientists and entrepreneurs in the commercialisation of their ideas through the licensing of intellectual property, by leading the formation of new companies, providing facilities in the early stages, providing investment and encouraging co-investment to accelerate development, providing operational expertise and recruiting high-calibre management teams. It also runs an incubator in London that is the initial home for many of its technology spin-outs.
Since admission of its shares to trading on AIM in 2006, Innovations has raised more than £346.0 million of equity from investors, which has enabled it to invest in some of the most exciting spin-outs to come out of UK academic research. In addition, the Group has a £30.0 million loan facility from the European Investment Bank (EIB) for investment in biotech and therapeutics businesses.
During the period from admission on AIM up until 31 January 2015, Innovations has invested a total of £198.3 million across its portfolio companies, which have raised collectively investment of £926.8 million rising to £1.0 billion including post period end investments and commitments.
About Autifony Therapeutics Ltd - www.autifony.com
Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The company is focused on the development of high value, novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia. Autifony Therapeutics is funded by SV Life Sciences, Imperial Innovations, Pfizer Venture Investments, International Biotechnology Trust PLC and UCL Business.
This information is provided by RNS
The company news service from the London Stock Exchange
END
http://otp.investis.com/clients/uk/...s/regulatory-story.aspx?cid=859&newsid=507565
Christian78
Member
- Dec 17, 2013
- 965
- Tinnitus Since
- (Sep 2013)
- Cause of Tinnitus
- progressive tinnitus, time of expiring in next 3-6 months
I think those pills will not work for vegetarians or vegans, and autifony will work best on those who take poultry with it but strongly avoid fish
Christian78
Member
- Dec 17, 2013
- 965
- Tinnitus Since
- (Sep 2013)
- Cause of Tinnitus
- progressive tinnitus, time of expiring in next 3-6 months
and they are extra sensitive on Omega 3 whatever is that... i suppose something that fish eat some plant
I wonder , it Autifony really works but after using it 1 years you lose complete sexual drive (you cant perform any sexual activities) would people take it???
This guy Atlantis has so COOOL nickname, I love atlantis, stargate atlantis, i been making logos for them and on my computer cut stickers... now i wonder how to steal his nickname
and they are extra sensitive on Omega 3 whatever is that... i suppose something that fish eat some plant
I wonder , it Autifony really works but after using it 1 years you lose complete sexual drive (you cant perform any sexual activities) would people take it???
This guy Atlantis has so COOOL nickname, I love atlantis, stargate atlantis, i been making logos for them and on my computer cut stickers... now i wonder how to steal his nickname
Stargate is pretty awesome! And I wouldn't know, Campral causes ETD.
Christian78
Member
- Dec 17, 2013
- 965
- Tinnitus Since
- (Sep 2013)
- Cause of Tinnitus
- progressive tinnitus, time of expiring in next 3-6 months
ETD, then i need to give it to my ex friend... that person celebrated 700 people in 3 years 2 months ago...
I also obtain it "legally" in Croatia, they biu it in pharmacy and send it to me, in south Bosnian (croatian part also), In Austria too, Serbia get all from east (they have general warehouse in Kraljevo
)or Sweden
Please stop polluting this thread with stories of infidelity feats or whatever lol.
This was posted in another thread:
http://www.enttoday.org/article/drug-trials-for-hearing-loss-tinnitus-therapies-show-promise/
http://www.enttoday.org/article/drug-trials-for-hearing-loss-tinnitus-therapies-show-promise/
I dont know where Autifony got the info that 18 month is the time period for shift of tinnitus from a peripheral issue a central one:
The U.K.-based study began in October 2014, according to Dr. Domayne-Hayman, and seeks to improve tinnitus in patients who have experienced symptoms for at least six months, but no more than 18 months, from diagnosis. That is the point in time, she noted, when the condition has shifted from one caused by localized damage to hair cells in the inner ear to a more centralized problem mediated by the central nervous system and brain.
The U.K.-based study began in October 2014, according to Dr. Domayne-Hayman, and seeks to improve tinnitus in patients who have experienced symptoms for at least six months, but no more than 18 months, from diagnosis. That is the point in time, she noted, when the condition has shifted from one caused by localized damage to hair cells in the inner ear to a more centralized problem mediated by the central nervous system and brain.
Dubbyaman
Member
So im confused. Is Autifonys main aim hearing loss in hopes to help t as a secondary? Even if the drug does tackle t in an effective way, alot of people will be way past the 18 month mark by the time it hits the market.
Their drug does not attempt and will not restore hearing sensitivity. It aims to improve speech processing in noisy situations by modulating potassium channels. It also targets tinnitus since K+ channels seem to be involved in this pathology as far as we know.
Nah that's the time period when it shifts from a localized problem to CNS problem, Autifony is targeting chronic tinnitus so even if your past the 18 month period it still will be effective because this drug is targeting the brain. While the other drugs will target the ear (AM-101) to treat acute tinnitus, when it is localized in the ear. But I believe if these drugs are effective that the combo of the two might just cure tinnitus, because it will address the ear's damage and the brain's dysfunction, hopefully curing tinnitus once and for all, or at least significantly reducing it. So no worries Autifony has us chronic sufferers covered, we will hear silence once again!!! (note* be positive people medicine will get us there).
Dubbyaman
Member
My T sounds the same today like at onset. And sometimes it goes milder or even louder.
I doubt there is something like a 18 month barrier where things change.
T is for me a brain thing (stress changed something in my brain triggering T).
As soon as I take the right pills calming nerves, T also goes down.
100% agree! Although, I'm hoping on phase 3 they take on people who've had it for many more moons.
Log in or register to get the full forum benefits!
Similar threads
